Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 12/20 | 0.54 |
| ▸ | METTL3 | Q86U44 | 5/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640950 | 0.86 | ADK (0.54) | ADKRETLCKSRC | |
| SCHEMBL29780875 | 0.86 | ADK (0.52) | ADKMETTL3RETLCKSRC | |
| SCHEMBL16769982 | 0.86 | ADK (0.52) | ADKMETTL3RETLCKSRC | |
| SCHEMBL1942725 | 0.84 | ADK (0.52) | ADKRETLCKSRCTEK | |
| SCHEMBL870154 | 0.82 | METTL3 (0.58) | ADKMETTL3RETRAPGEF3LCK | |
| SCHEMBL20351758 | 0.82 | ADK (0.54) | ADKRETSLC29A1 | |
| SCHEMBL20351760 | 0.82 | ADK (0.55) | ADKRETSLC29A1LCKSRC | |
| SCHEMBL16769692 | 0.81 | ADK (0.50) | ADKMETTL3RETSLC29A1LCK | |
| SCHEMBL18925738 | 0.80 | ADK (0.47) | ADKMETTL3RETLCKSRC | |
| SCHEMBL16769694 | 0.80 | ADK (0.47) | ADKMETTL3RETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561260-A | Heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| CN-116583287-A | Pyridazinone heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023016296-A1 | HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2022166610-A1 | PYRIDAZINONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| EP-3487503-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | ADK 1509/4885METTL3 4319/4885RET 2772/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | ADK 1509/4885METTL3 4319/4885RET 2772/4885 |
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | PSEN1, CPT1A, IRS1 | ADK 2534/4885METTL3 4335/4885RET 249/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ADK 557/4885METTL3 2612/4885RET 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.